These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
179 related articles for article (PubMed ID: 16842259)
1. Pathological response of gastrointestinal stromal tumour to imatinib treatment correlates with tumour KIT mutational status in individual tumour clones. Loughrey MB; Beshay V; Dobrovic A; Zalcberg J; Waring PM Histopathology; 2006 Jul; 49(1):99-100. PubMed ID: 16842259 [No Abstract] [Full Text] [Related]
2. Pathological changes related to Imatinib treatment in a patient with a metastatic gastrointestinal stromal tumour. Abdulkader I; Cameselle-Teijeiro J; Forteza J Histopathology; 2005 Apr; 46(4):470-2. PubMed ID: 15810964 [No Abstract] [Full Text] [Related]
3. KIT immunohistochemistry and mutation status in gastrointestinal stromal tumours (GISTs) evaluated for treatment with imatinib. Loughrey MB; Trivett M; Beshay V; Dobrovic A; Kovalenko S; Murray W; Lade S; Turner H; McArthur GA; Zalcberg J; Waring PM Histopathology; 2006 Jul; 49(1):52-65. PubMed ID: 16842246 [TBL] [Abstract][Full Text] [Related]
4. [Study on the mechanism of imatinib-induced resistance in gastrointestinal stromal tumors]. Zhou Y; Hou YY; Tan YS; Lu SH; Hou J; Liu JL; Qin J; Shen KT; Sun YH Zhonghua Zhong Liu Za Zhi; 2009 Aug; 31(8):597-601. PubMed ID: 20021947 [TBL] [Abstract][Full Text] [Related]
5. Kinase mutations and imatinib mesylate response for 64 Taiwanese with advanced GIST: preliminary experience from Chang Gung Memorial Hospital. Yeh CN; Chen TW; Lee HL; Liu YY; Chao TC; Hwang TL; Jan YY; Chen MF Ann Surg Oncol; 2007 Mar; 14(3):1123-8. PubMed ID: 17195905 [TBL] [Abstract][Full Text] [Related]
6. c-Kit/PDGFRA gene status alterations possibly related to primary imatinib resistance in gastrointestinal stromal tumors. Miselli FC; Casieri P; Negri T; Orsenigo M; Lagonigro MS; Gronchi A; Fiore M; Casali PG; Bertulli R; Carbone A; Pierotti MA; Tamborini E; Pilotti S Clin Cancer Res; 2007 Apr; 13(8):2369-77. PubMed ID: 17438095 [TBL] [Abstract][Full Text] [Related]
7. A prospective, multicenter, phase 2 study of imatinib mesylate in korean patients with metastatic or unresectable gastrointestinal stromal tumor. Ryu MH; Kang WK; Bang YJ; Lee KH; Shin DB; Ryoo BY; Roh JK; Kang JH; Lee H; Kim TW; Chang HM; Park JO; Park YS; Kim TY; Kim MK; Lee WK; Kang HJ; Kang YK Oncology; 2009; 76(5):326-32. PubMed ID: 19307738 [TBL] [Abstract][Full Text] [Related]
8. Management of metastatic gastrointestinal stromal tumour in the Glivec era: a practical case-based approach. Harrison ML; Goldstein D Intern Med J; 2006 Jun; 36(6):367-77. PubMed ID: 16732863 [TBL] [Abstract][Full Text] [Related]
9. Double resistance to imatinib and AMG 706 caused by multiple acquired KIT exon 17 mutations in a gastrointestinal stromal tumour. Grabellus F; Ebeling P; Worm K; Sheu SY; Antoch G; Frilling A; Schmid KW Gut; 2007 Jul; 56(7):1025-6. PubMed ID: 17566038 [No Abstract] [Full Text] [Related]
10. [Activating mutations in receptor tyrosine kinases with relevance for treatment of gastrointestinal stromal tumors]. Wardelmann E; Merkelbach-Bruse S; Büttner R; Schildhaus HU Verh Dtsch Ges Pathol; 2007; 91():165-8. PubMed ID: 18314611 [TBL] [Abstract][Full Text] [Related]
11. Different factors are responsible for predicting relapses after primary tumors resection and for imatinib treatment outcomes in gastrointestinal stromal tumors. Rutkowski P; Debiec-Rychter M; Nowecki ZI; Wozniak A; Michej W; Limon J; Siedlecki JA; Jerzak Vel Dobosz A; Grzesiakowska U; Nasierowska-Guttmejer A; Sygut J; Nyckowski P; Krawczyk M; Ruka W Med Sci Monit; 2007 Nov; 13(11):CR515-522. PubMed ID: 17968300 [TBL] [Abstract][Full Text] [Related]
12. Gastrointestinal stromal tumour treated with neoadjuvant imatinib. Loughrey MB; Mitchell C; Mann GB; Michael M; Waring PM J Clin Pathol; 2005 Jul; 58(7):779-81. PubMed ID: 15976351 [TBL] [Abstract][Full Text] [Related]
14. Imatinib-associated tumour response in a dog with a non-resectable gastrointestinal stromal tumour harbouring a c-kit exon 11 deletion mutation. Kobayashi M; Kuroki S; Ito K; Yasuda A; Sawada H; Ono K; Washizu T; Bonkobara M Vet J; 2013 Oct; 198(1):271-4. PubMed ID: 23820134 [TBL] [Abstract][Full Text] [Related]
15. Acquired resistance to imatinib in gastrointestinal stromal tumours caused by multiple KIT mutations. Wardelmann E; Thomas N; Merkelbach-Bruse S; Pauls K; Speidel N; Büttner R; Bihl H; Leutner CC; Heinicke T; Hohenberger P Lancet Oncol; 2005 Apr; 6(4):249-51. PubMed ID: 15811621 [No Abstract] [Full Text] [Related]
16. Cell cycle/apoptosis molecule expression correlates with imatinib response in patients with advanced gastrointestinal stromal tumors. Romeo S; Debiec-Rychter M; Van Glabbeke M; Van Paassen H; Comite P; Van Eijk R; Oosting J; Verweij J; Terrier P; Schneider U; Sciot R; Blay JY; Hogendoorn PC; Clin Cancer Res; 2009 Jun; 15(12):4191-8. PubMed ID: 19509155 [TBL] [Abstract][Full Text] [Related]
17. [GIST: a clinical case as a model of surgical and pharmacological therapy of solid tumours]. D'Amato A; Pezzoli F; Caterino S; Cavallini M; Balducci G; Bocchetti T; Ziparo V Chir Ital; 2005; 57(4):509-14. PubMed ID: 16060192 [TBL] [Abstract][Full Text] [Related]
18. [Effect of c-kit mutation on the prognosis of gastrointestinal stromal tumors: a meta-analysis]. Zhao WY; Cao H; Zhang Y; Shen ZY; Wu ZY Zhonghua Wai Ke Za Zhi; 2009 Jun; 47(11):857-62. PubMed ID: 19961019 [TBL] [Abstract][Full Text] [Related]